The treatment of Helicobacter pylori infection

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue SUPPL. 1, 1997, Pages 35-41

  Pounder, R E ^a   Williams, M P ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

BACTERIAL INFECTION; BREATH ANALYSIS; CLINICAL TRIAL; CONFERENCE PAPER; DYSPEPSIA; HELICOBACTER PYLORI; HUMAN; LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; STOMACH CANCER;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; CLINICAL TRIALS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DYSPEPSIA; H(+)-K(+)-EXCHANGING ATPASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA; RANITIDINE; RISK FACTORS; STOMACH NEOPLASMS;

EID: 0030956177     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.11.s1.9.x     Document Type: Article

References (35)

1. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994; 272: 65-9.
2. Veldhuyzen van Zanten SJO. The role of Helicobacter pylori infection in non-ulcer dyspepsia. Aliment Pharmacol Ther 1997; 11 (Suppl. 1): 63-9.
3. Uemura N, Mukai T, Okamoto S, et al. Helicobacter pylori eradication inhibits the growth of intestinal type of gastric cancer in initial stage. Gastroenterology 1996; 110: A282 (Abstract).
4. Borody TJ, Andrews P, Jankiewicz E, Ferch N, Carroll M. Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori. Am J Gastroenterol 1993; 88: 1266-8.
5. Griffiths AE, Thursz MR, Pryce D, Walker DD. Do gastric atrophy and intestinal metaplasia regress in the long-term following treatment for Helicobacter pylori? Gut 1996; 39 (Suppl. 1): W8 (Abstract).
6. Forman D. The prevalence of Helicobacter pylori infection in gastric cancer. Aliment Pharmacol Ther 1995; 9: 71-6.
7. Isaacson PG. Gastric lymphoma and Helicobacter pylori. N Engl J Med 1994; 330: 1310-11.
8. Solcia E, Fiocca R, Havu N, Dalvag A, Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992; 51 (Suppl. 1): 82-92.
9. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356-70.
10. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux oesophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
11. Hackelsberger A, Miehlke S, Lehn N, et al. Helicobacter pylori eradication vs. short term acid suppression; long term consequences for gastric body mucosa. Gastroenterology 1996; 110: A127 (Abstract).
12. Eissele R, Brunner G, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole : Helicobacter pylori is a major risk factor for argyrophil-cell hyperplasia. Gastroenterology 1996; 110: A101 (Abstract).
13. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux oesophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
14. Isenberg JI, Peterson WL, Elashoff JD, et al. Healing of benign gastric ulcer with low-dose antacid or cimetidine. N Engl J Med 1983; 308: 1319-24.
15. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-52.
16. Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716-27.
17. Tytgat GNJ. Review article : treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359-69.
18. Penston JG. Review article: Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994; 8: 369-90.
19. Dixon JS. Helicobacter pylori eradication: unravelling the facts. ScandJ Gastroenterol 1995; 30 (Suppl. 212): 48-62.
20. Harris AW, Misiewicz JJ. Eradication of Helicobacter pylori. Ballières Clin Gastroenterol 1995; 9: 583-613.
21. van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996; 1: 6-19
22. Lind T, Veldhuyzen van Xanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1996; 1: 138-44.
23. 2-antagonist activity, on 24-hour intragastric acidity. Aliment Pharmacol Ther 1991; 5: 481-90.
24. Stables R, Campbell CJ, Clayton NM, et al. Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate. Aliment Pharmacol Ther 1993; 7: 237-46.
25. Lacey LF, Frazer NM, Keene ON, Smith JT. Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR123311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB). Eur J Clin Pharmacol 1994; 47: 177-80.
26. McColm AA, McLaren A, Klinkert G, et al. Ranitidine bismuth citrate: a novel anti-ulcer agent with different physicochemical characteristics and improved biological activity to a bismuth citrate-ranitidine admixture. Aliment Pharmacol Ther 1996; 10: 241-50.
27. Koch KM, Kerr BM, Gooding AE, Davis IM. Pharmacokinetics of bismuth and ranitidine following multiple doses of ranitidine bismuth citrate. Br J Clin Pharmacol 1996; 42: 207-11.
28. Bardhan KD, Dekkers CPM, Nowak A, et al. GR122311X (ranitidine bismuth citrate) a new drug for the treatment of duodenal ulcer. Aliment Pharmacol Ther 1995; 9: 497-506.
29. Logan RPH, Gummett PA, Misiewicz JJ, et al. The efficacy of ranitidine bismuth citrate (GR122311X) in the treatment of Helicobacter pylori infection. Gastroenterology 1992; 102 (Part 2): A114 (Abstract).
30. Wyeth JW, Pounder RE, Duggan AE, et al. The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996; 10: 623-30.
31. Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD and the RBC H. pylori Study Group. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing their recurrence. Aliment Pharmacol Ther 1996; 10: 251-61.
32. Bardhan KD, Dallaire C, Eisold H, Duggan AE. The treatment of duodenal ulcer with GR122311X (ranitidine bismuth citrate) and clarithromycin. Gut 1995; 37 (Suppl. 1): A5 (Abstract).
33. Pounder RE, Bailey R, Louw JA, et al. GR122311X (ranitidine bismuth citrate) with clarithromycin for the eradication of Helicobacter pylori. Gut 1995; 37 (Suppl. 1): A42 (Abstract).
34. Axon ATR, Ireland A, Lancaster-Smith MJ, Roopram PD. Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1997; 11: 81-7.
35. Bardhan KD, Wurzer H, Marcelino M, Jahnsen J, Lotay N. High cure rates with ranitidine bismuth citrate (Pylorid) plus clarithromycin given twice daily. Gut 1996; 39 (Suppl. 2): A36 (Abstract).